Merck's $11.5 billion bet on its next big drug finally arrives : vimarsana.com

The newly approved drug, which treats potentially fatal pulmonary arterial hypertension, is estimated to ring up as much as $7.5 billion in yearly sales.

Related Keywords

Jessica Huston , Rob Davis , Drug Administration , Chief Executive Rob Davis , Ascension Saint Thomas Heart , Merck , Lung Disease , Winrevair , Pulmonary Arterial Hypertension , High Blood Pressure ,